Melanoma (Skin)
Conditions
Brief summary
The choice of treatment of patients with metastatic melanoma depends on the status of B-RAF of the tumor: in the absence of mutation, treatment with immunotherapy (currently anti-PD1) is proposed in the first line; When B-RAF is mutated, treatment with targeted therapies is retained: B-RAF and MEK inhibitors are prescribed in combination (vemurafenib + cobimetinib or dabrafenib + trametinib). Patient response rates for targeted therapies range from 50 to 60%, and the occurrence of sometimes severe side effects is not predictable. There are currently no predictive biomarkers of patients' response to targeted therapy molecules. The in vitro evaluation of the intrinsic sensitivity of the cells of patients to different combinations of targeted therapy molecules would make it possible to propose the best therapeutic combinations. The cutaneous metastases are chosen in the model because of easy access to collect tumor tissue. The most relevant in vitro models for mimicking cutaneous melanoma metastases are explant cultures and human skin equivalents.
Interventions
OTHERDevelopment of the most specific physiologically relevant experimental patient models
Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Major Patients, * patients with melanoma (stage IV) with cutaneous metastases, * seronegative HIV, HBV, HCV, HTLV1.
Exclusion criteria
* Absence of cutaneous metastasis or in transit * HIV or HBV or HCV or HTLV1 seropositivity * Patient minor, patient under guardianship or curatorship
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluating in vitro the response of tumor cells to different combinations of targeted therapy molecules | 30 months |
Countries
France
Outcome results
None listed